A detailed history of Fox Run Management, L.L.C. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 14,973 shares of CCCC stock, worth $89,838. This represents 0.01% of its overall portfolio holdings.

Number of Shares
14,973
Previous 41,732 64.12%
Holding current value
$89,838
Previous $340,000 79.71%
% of portfolio
0.01%
Previous 0.08%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$4.05 - $8.1 $108,373 - $216,747
-26,759 Reduced 64.12%
14,973 $69,000
Q1 2024

May 13, 2024

BUY
$5.3 - $11.0 $221,179 - $459,052
41,732 New
41,732 $340,000
Q2 2022

Aug 12, 2022

SELL
$5.06 - $26.46 $45,165 - $236,181
-8,926 Closed
0 $0
Q1 2022

May 10, 2022

BUY
$19.99 - $33.23 $178,430 - $296,610
8,926 New
8,926 $217,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $293M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.